Finance entity
earnings is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Axon Enterprise, the most common co-covered peer. They are better corroborated than the beat average, carrying 3 original sources each against 2.5 for the same window.
Last mentioned: Feb 23, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
earnings is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Axon Enterprise, the most common co-covered peer. They are better corroborated than the beat average, carrying 3 original sources each against 2.5 for the same window. At 5, the average consequence score sits below the same-window beat average of 6.4. Corcept Therapeutics appears in 1 tracked Finance story from February 23, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 57 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Corcept Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Axon Enterprise is set to report Q4 2025 results, with investors focused on the adoption of AI-driven tools like Draft One and the continued rollout of TASER 10. Meanwhile, specialty pharma players Corcept and Supernus prepare to disclose their own year-end performance amid shifting regulatory and competitive landscapes.
Corcept Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
